Cefoperazone therapy of complicated urinary tract infections: pharmacokinetics in renal transplant recipients.
Cefoperazone was used to treat patients with complicated urinary tract infections due to multiple antibiotic-resistant gram-negative rods who had failed prior courses of intravenous antibiotic therapy. Cure was achieved in 44% (4/9) of cases; 44% of patients improved but relapsed and 11% (1/9) of patients were reinfected. Relapse and reinfection were associated with Pseudomonas aeruginosa and/or with conditions not normally responsive to medical therapy alone including prostatitis, reflux and chronic indwelling Foley catheters. The pharmacokinetics of cefoperazone were studied in renal transplant recipients. Peak serum concentrations (range 146-241 micrograms/ml) and 2-hour noncumulative urine concentrations (range 161-291 micrograms/ml) exceeded the minimal inhibitory concentrations of the bacteria in all cases. There was no accumulation of cefoperazone despite the presence of impaired renal function.
D000328:Adult; D000368:Aged; D002438:Cefoperazone / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D003404:Creatinine / Q000652:urine; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D016030:Kidney Transplantation; D007700:Kinetics; D007710:Klebsiella Infections / Q000188:drug therapy; D007711:Klebsiella pneumoniae; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy; D011704:Pyelonephritis / Q000188:drug therapy; D012706:Serratia marcescens; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy*
D002438:Cefoperazone; D003404:Creatinine